Monopar director exercises, sells 3,142 shares
Monopar Therapeutics (MNPR) director Raymond Anderson amended a prior insider report to include previously omitted option exercises and to reflect Monopar’s 5-for-1 reverse stock split effective August 12, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) director Raymond Anderson amended a prior insider report to include previously omitted option exercises and to reflect Monopar’s 5-for-1 reverse stock split effective August 12, 2024. On August 25, 2026, he exercised options for 3,142 shares of common stock at a $30.00 exercise price and sold 3,142 shares in three open-market transactions at weighted average prices of $110.04, $111.07, and $113.05. All transactions were effected under a Rule 10b5-1 trading plan executed on May 26, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,142 shares ($258K approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Anderson Raymond
Role
Director
Sold
3,142 shs ($352K)
Approx. gross sale proceeds
$352K
Approx. exercise cost
$94K
Approx. pre-tax spread
$258K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F2 | 1,402 | $0.00 | $0.00 |
| Exercise | Stock Option F1, F3 | 1,740 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,402 | $30.00 | $42K |
| Exercise | Common Stock F1 | 1,740 | $30.00 | $52K |
| Sale | Common Stock F1, F4 | 694 | $110.04 | $76K |
| Sale | Common Stock F1, F5 | 646 | $111.07 | $72K |
| Sale | Common Stock F1, F6 | 1,802 | $113.05 | $204K |
Holdings After Transaction:
Stock Option — 6,283 contracts (Direct);
Common Stock — 5,373 shares (Direct)
Footnotes (6)
- F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.
- F2. On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.
- F3. On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Key Figures
Options exercised: 3,142 shares of Common Stock
Exercise price: $30.00 per share
Shares sold at $110.04: 694 shares at $110.04 per share
+5 more
8 metrics
Options exercised
3,142 shares of Common Stock
Total underlying shares from two option exercises on August 25, 2026
Exercise price
$30.00 per share
Conversion or exercise price for both stock option series
Shares sold at $110.04
694 shares at $110.04 per share
Weighted average sale price; trades between $109.51 and $110.43 on August 25, 2026
Shares sold at $111.07
646 shares at $111.07 per share
Weighted average sale price; trades between $110.56 and $111.41 on August 25, 2026
Shares sold at $113.05
1,802 shares at $113.05 per share
Weighted average sale price; trades between $112.84 and $113.11 on August 25, 2026
Reverse stock split ratio
5 to 1 reverse stock split
Reverse split of Monopar Therapeutics common stock effective August 12, 2024
2017 option grant size
4,205 shares
Maximum shares purchasable under September 18, 2017 stock option grant
2018 option grant size
5,220 shares
Maximum shares purchasable under August 9, 2018 stock option grant
Key Terms
Rule 10b5-1 Plan, reverse stock split, weighted average price, stock options, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 Plan executed"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
reverse stock split financial
"did not account for Monopar Therapeutics Inc.'s 5 to 1 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"the reporting person was granted stock options to purchase up to 4,205 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vesting financial
"The options vest 6/42nds at the six-month anniversary of grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MNPR director Raymond Anderson report in this amended Form 4?
He reported option exercises for 3,142 shares of Monopar Therapeutics common stock at a $30.00 exercise price and sales of 3,142 shares in three open-market transactions on August 25, 2026, at weighted average prices of $110.04, $111.07, and $113.05.
Why did Monopar Therapeutics (MNPR) file an amended Form 4?
The amended Form 4 states that an earlier filing omitted two option exercises that occurred before the reported stock sales and did not account for Monopar’s 5-for-1 reverse stock split effective August 12, 2024. Share amounts were adjusted to reflect the split.
Were the MNPR insider transactions made under a Rule 10b5-1 plan?
Yes. The filing states that both the option exercises and the stock sales on August 25, 2026 were effected pursuant to a Rule 10b5-1 trading plan executed by Raymond Anderson on May 26, 2026.
What stock options did the MNPR director exercise in this Form 4/A?
Raymond Anderson exercised 1,402 options (grant dated September 18, 2017, expiring September 17, 2027) and 1,740 options (grant dated August 9, 2018, expiring August 8, 2028). Both series had a $30.00 per share exercise price and converted into common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
